CEO Appointment & Name Change Thalia Therapeutics

AI SummaryClose X

N4 Pharma plc is transitioning to a therapeutic biotechnology company, proposed to be renamed Thalia Therapeutics, and has appointed Dr. David H. Solomon as CEO to drive the development of RNA-based therapeutics and its Nuvec® delivery platform. The company is initiating a program for a dual-acting siRNA targeting PCSK9 and Lp(a) to reduce cardiovascular risk, a market projected to grow significantly. This strategic shift involves advancing internally generated assets and exploring new opportunities, while development of ECP105 is paused. Dr. Solomon brings extensive leadership experience in biotechnology, including previous roles at Zealand Pharma and Silence Therapeutics, and has a strong track record in R&D, business development, and financing.

Disclaimer*

UK 100

Latest directors dealings